Page last updated: 2024-11-05

thalidomide and Central Nervous System Diseases

thalidomide has been researched along with Central Nervous System Diseases in 8 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19905 (62.50)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Duzova, A1
Bakkaloglu, A1
Ahn, SW1
Kim, KT1
Youn, YC1
Kwon, OS1
Kim, YB1
MICHAELIS, R1
TARNOW, G1
Broekaert, SM1
Metzler, G1
Burgdorf, W1
Röcken, M1
Schaller, M1
Archer, J1
Naafs, B1
Faber, WR1
Amelung, W1
Püntmann, E1
Horstmann, W1

Reviews

1 review available for thalidomide and Central Nervous System Diseases

ArticleYear
Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment.
    Current pharmaceutical design, 2008, Volume: 14, Issue:13

    Topics: Anticonvulsants; Central Nervous System Diseases; Child; Cyclophosphamide; Drug Therapy, Combination

2008

Other Studies

7 other studies available for thalidomide and Central Nervous System Diseases

ArticleYear
Isolated spinal cord neurosarcoidosis diagnosed by cord biopsy and thalidomide trial.
    Journal of Korean medical science, 2011, Volume: 26, Issue:1

    Topics: Adrenal Cortex Hormones; Biopsy; Central Nervous System Diseases; Female; Humans; Immunosuppressive

2011
[NEUROLOGICAL DISEASES AS SEQUELS TO CONTERGAN USE IN DISORDERS OF INTESTINAL RESORPTION].
    Der Nervenarzt, 1963, Volume: 34

    Topics: Central Nervous System Diseases; Gastric Acidity Determination; Gastritis; Intestinal Diseases; Neur

1963
Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide.
    American journal of clinical dermatology, 2007, Volume: 8, Issue:5

    Topics: Anti-Inflammatory Agents; Central Nervous System Diseases; Female; Histiocytosis, Langerhans-Cell; H

2007
Thalidomide and neurological damage revisited.
    JAMA, 1978, Apr-21, Volume: 239, Issue:16

    Topics: Abnormalities, Drug-Induced; Central Nervous System Diseases; Female; Fetus; Humans; Infant, Newborn

1978
Thalidomide therapy. An open trial.
    International journal of dermatology, 1985, Volume: 24, Issue:2

    Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu

1985
[Clinical aspects and therapy of the so-called Contergan-polyneuropathy].
    Der Nervenarzt, 1966, Volume: 37, Issue:5

    Topics: Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Nerve Degeneration;

1966
[Reference to central nervous system damage within the context of thalidomide embryopathy. Pathological-anatomic, electroencephalographic and neurologic findings].
    Zeitschrift fur Kinderheilkunde, 1966, Volume: 96, Issue:4

    Topics: Abnormalities, Drug-Induced; Central Nervous System Diseases; Child, Preschool; Ear Deformities, Acq

1966